Nuvation Bio NUVB Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Nuvation Bio (NUVB) reported deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost of $8.87M in Q4 2025.
- How has Nuvation Bio's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost changed year-over-year?
- Nuvation Bio's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost decreased by 32.6% year-over-year, from $13.17M to $8.87M.
- What is the long-term trend for Nuvation Bio's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Over 5 years (2020 to 2025), Nuvation Bio's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost has grown at a 91.9% compound annual growth rate (CAGR), from $341K to $8.87M.